Cargando…

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole

ESR1 mutations are frequently acquired in hormone-resistant metastatic breast cancer (MBC). CDK4/6 inhibition along with endocrine therapy is a promising strategy in hormone receptor-positive MBC. However, the incidence and impact of ESR1 mutations on clinical outcome in patients treated with CDK4/6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gyanchandani, Rekha, Kota, Karthik J., Jonnalagadda, Amruth R., Minteer, Tanya, Knapick, Beth A., Oesterreich, Steffi, Brufsky, Adam M., Lee, Adrian V., Puhalla, Shannon L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620144/ https://www.ncbi.nlm.nih.gov/pubmed/28978004 http://dx.doi.org/10.18632/oncotarget.11383

Ejemplares similares

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
por: Brufsky, Adam, et al.
Publicado: (2021)

Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification
por: Kota, Karthik, et al.
Publicado: (2017)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
por: Brufsky, Adam, et al.
Publicado: (2022)

Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood
por: Gyanchandani, Rekha, et al.
Publicado: (2018)

Targeted mutation detection in breast cancer using MammaSeq™
por: Smith, Nicholas G., et al.
Publicado: (2019)

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
por: DeMichele, Angela, et al.
Publicado: (2021)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario
por: Orbaugh,1, Kristi, et al.
Publicado: (2016)

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Puhalla, Shannon, et al.
Publicado: (2008)

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
por: Darvishi, Ali, et al.
Publicado: (2023)

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom
por: Suri, Gaurav, et al.
Publicado: (2019)

Acute Lymphoblastic Leukemia in a Patient Treated with Letrozole and Palbociclib
por: Park, Jin Hyun, et al.
Publicado: (2019)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
por: Bahreini, Amir, et al.
Publicado: (2017)

Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss
por: Frisone, Daniele, et al.
Publicado: (2019)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
por: Kota, Karthik, et al.
Publicado: (2017)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer
por: Puthanmadhom Narayanan, Susrutha, et al.
Publicado: (2023)

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
por: Brufsky, Adam, et al.
Publicado: (2023)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
por: Steinman, Richard A, et al.
Publicado: (2012)

A Case of Late-Onset Gemcitabine Lung Toxicity
por: Sherrod, Amanda M., et al.
Publicado: (2011)

Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
por: Sun, Maoben, et al.
Publicado: (2023)

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
por: Fein, Luis, et al.
Publicado: (2023)

Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study
por: Masuda, Norikazu, et al.
Publicado: (2018)

Surgery to Oligometastatic Breast Cancer after Excellent Response to Palbociclib and Letrozole Therapy: Pitfall of Ultrasound Therapeutic Evaluation
por: Fujii, Suzuka, et al.
Publicado: (2021)

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
por: Im, Seock-Ah, et al.
Publicado: (2019)

Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
por: Fein, Luis, et al.
Publicado: (2023)

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
por: Rugo, H S, et al.
Publicado: (2018)

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application
por: Posocco, Bianca, et al.
Publicado: (2020)

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
por: Brufsky, Adam, et al.
Publicado: (2023)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020)

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
por: Dhakal, Ajay, et al.
Publicado: (2020)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
por: Darrigues, Lauren, et al.
Publicado: (2021)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_35gcegq68i5odfe57s4ouohe3a